Search
Search Results
-
Image-guided moderately hypofractionated radiotherapy for localized prostate cancer: a multicentric retrospective study (IPOPROMISE)
BackgroundModerate hypofractionated radiotherapy is a treatment option for the cure of localized prostate cancer (PCa) patients based on the results...
-
Long-term outcomes of high-dose-rate brachytherapy and external beam radiotherapy without hormone therapy for high-risk localized prostate cancer
PurposeUntil March 2018, patients with high-risk localized prostate cancer had been administered high-dose-rate brachytherapy (HDR-BT) combined with...
-
Robotic stereotactic body radiotherapy for localized prostate cancer: final analysis of the German HYPOSTAT trial
PurposeWe report results of the first German prospective multicenter single-arm phase II trial (ARO 2013-06; NCT02635256) of hypofractionated robotic...
-
Using PSMA imaging for prognostication in localized and advanced prostate cancer
The use of prostate-specific membrane antigen (PSMA)-directed applications in modern prostate cancer management has evolved rapidly over the past few...
-
Patient-reported outcomes before treatment for localized prostate cancer: are there differences among countries? Data from the True North Global Registry
IntroductionSimilar Patient-Reported Outcomes (PROs) at diagnosis for localized prostate cancer among countries may indicate that different...
-
Accuracy of combined multi-parametric MRI and PSMA PET-CT in diagnosing localized prostate cancer: newer horizons for a biopsy-free pathway
IntroductionProstate-specific antigen (PSA) is a reliable biomarker for identification of prostate cancer, although a biopsy is still the gold...
-
The march toward single-fraction stereotactic body radiotherapy for localized prostate cancer—Quo Vadimus?
PurposeStereotactic body radiotherapy (SBRT) is an emerging treatment option for localized prostate cancer. There is increasing interest to reduce...
-
Associations of role, area deprivation index, and race with health behaviors and body mass index among localized prostate cancer patients and their partners
PurposeTo examine the associations of role (localized prostate cancer (PCa) patient vs. their intimate partner), area deprivation index (ADI—higher...
-
Coadministration of Apalutamide and Relugolix in Patients with Localized Prostate Cancer at High Risk for Metastases
BackgroundThe single-arm, open-label, multicenter, phase II Apa-RP study evaluates the biochemical recurrence (confirmed prostate-specific antigen...
-
First experiences using transurethral ultrasound ablation (TULSA) as a promising focal approach to treat localized prostate cancer: a monocentric study
PurposeTo share our experience using transurethral ultrasound ablation (TULSA) treatment for focal therapy of localized prostate cancer (PCa).
...
-
Six-year outcomes of robot-assisted radical prostatectomy versus volumetric modulated arc therapy for localized prostate cancer: A propensity score-matched analysis
BackgroundAlthough robot-assisted radical prostatectomy (RARP) and intensity-modulated radiotherapy are the leading respective techniques of...
-
Adjusting the duration of androgen deprivation therapy (ADT) based on nadir PSA for high risk localized prostate cancer patients treated with definitive external beam radiation therapy and ADT
BackgroundA nadir Prostate-Specific Antigen (nPSA) of 0.06 ng/mL has been shown to be a strong independent predictor of biochemical recurrence-free...
-
Preoperative endogenous total testosterone predicts prostate cancer progression: results in 580 consecutive patients treated with robot assisted radical prostatectomy for clinically localized disease
PurposeTo test the role of endogenous total testosterone (ETT) as a predictor of prostate cancer (PCa) progression in patients treated with robot...
-
Single-center, prospective phase 2 trial of high-intensity focused ultrasound (HIFU) in patients with unilateral localized prostate cancer: good functional results but oncologically not as safe as expected
PurposeFocal therapy (FT) for localized prostate cancer (PCa) is only recommended within the context of clinical trials by international guidelines....
-
Acute and long-term toxicity in primary hypofractionated external photon radiation therapy in patients with localized prostate cancer
BackgroundCompelling evidence exists for the iso-effectiveness and safety of moderate hypofractionated radiotherapy (Hypo-RT) schedules [1, 2]....
-
Safety and efficacy associated with single-fraction high-dose-rate brachytherapy in localized prostate cancer: a systematic review and meta-analysis
ObjectiveAlthough single-fraction high-dose-rate brachytherapy (SFHDR) for localized prostate cancer has been tried in clinical trials, relevant...
-
Genetic testing and management of prostate cancer patients with pathogenic germline variants
Prostate cancer (PCa) is an androgen-receptor signaling-dependent disease with a subset of patients harboring pathogenic germline variants (PGVs) in...
-
Focal Therapy in Grade Group 3 Prostate Cancer
Purpose of this ReviewTreatment of intermediate risk prostate cancer remains controversial. Clearly some patients with low volume favorable...
-
Outcome comparison of radical prostatectomy versus seed brachytherapy for clinically localized prostate cancer using two biochemical recurrence definitions
ObjectiveWe compared the outcome of radical prostatectomy (RP) with seed brachytherapy (BT) in clinically localized prostate cancer (LPCa) using two...
